Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 6, 2026, 6:21 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2881–2904 of 10,825 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Developmental Defect Clear all

Conditions: Adverse Pregnancy Outcomes, Atopic Dermatitis
Interventions: dupilumab; Drug
Lead sponsor: Regeneron Pharmaceuticals; Industry
Eligibility: 18 Years to 49 Years · Female only
Enrollment: 12,343 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2026
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Breast Cancer
Interventions: Not listed
Lead sponsor: New York Presbyterian Hospital; Other
Eligibility: 18 Years and older · Female only
Enrollment: 2,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 1991
U.S. locations: 2
States / cities: New York, New York

Conditions: HIV Infections, Lipodystrophy, Hyperinsulinemia
Interventions: Metformin hydrochloride, Rosiglitazone maleate; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 65 Years
Enrollment: 105 participants
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 34
States / cities: Birmingham, Alabama • Los Angeles, California • Menlo Park, California + 20 more

Conditions: Hereditary Breast and Ovarian Cancer
Interventions: BRCA-Gist; Behavioral
Lead sponsor: Georgetown University; Other
Eligibility: 18 Years and older · Female only
Enrollment: 95 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2022
U.S. locations: 4
States / cities: Washington D.C., District of Columbia • Alexandria, Virginia • Richmond, Virginia

Conditions: Prader-Willi Syndrome
Interventions: DCCR, Placebo for DCCR; Drug
Lead sponsor: Soleno Therapeutics, Inc.; Industry
Eligibility: 4 Years and older
Enrollment: 127 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 20
States / cities: Orange, California • Palo Alto, California • San Diego, California + 17 more

Conditions: Dermatitis, Atopic
Interventions: GSK1070806, Placebo; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 8
States / cities: North Little Rock, Arkansas • Miami, Florida • Tampa, Florida + 5 more

Conditions: Hemophilia
Interventions: SureSource Engage application; Device
Lead sponsor: Healthcare Innovation Technology Lab; Industry
Eligibility: 18 Years to 63 Years
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: New York, New York

Conditions: Atopic Dermatitis, Atopic Dermatitis Eczema, Eczema
Interventions: IMG-007; Drug
Lead sponsor: Inmagene LLC; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 16
States / cities: Lancaster, California • Los Angeles, California • Ocala, Florida + 13 more

Conditions: Primary Immune Deficiency
Interventions: GC5107; Biological
Lead sponsor: GC Biopharma Corp; Industry
Eligibility: 2 Years to 16 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2026
U.S. locations: 5
States / cities: Aurora, Colorado • Centennial, Colorado • Dallas, Texas + 2 more

Conditions: Hereditary Angioedema
Interventions: Placebo, KVD900 600 mg, KVD900 300 mg; Drug
Lead sponsor: KalVista Pharmaceuticals, Ltd.; Industry
Eligibility: 12 Years and older
Enrollment: 136 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 22
States / cities: Birmingham, Alabama • Scottsdale, Arizona • Little Rock, Arkansas + 18 more

Conditions: Cystic Fibrosis, Exocrine Pancreatic Insufficiency
Interventions: GlycosBio Nutritional Supplement + PERT placebo, Standard Nutritional Supplement + PERT; Dietary Supplement
Lead sponsor: GlycosBio, Inc.; Industry
Eligibility: 12 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Sickle Cell Disease, Transfusion-dependent Beta-Thalassemia, Hemoglobinopathies
Interventions: Safety and efficacy assessments; Other
Lead sponsor: Editas Medicine, Inc.; Industry
Eligibility: 12 Years to 50 Years
Enrollment: 54 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2040
U.S. locations: 16
States / cities: Oakland, California • Aurora, Colorado • New Haven, Connecticut + 12 more

Conditions: Gaucher Disease
Interventions: no intervention; Other
Lead sponsor: University of Minnesota; Other
Eligibility: 18 Years to 80 Years
Enrollment: 30 participants
Timeline: 2023 – 2026
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Cystic Fibrosis
Interventions: VX-121/TEZ/D-IVA, ELX/TEZ/IVA, IVA, Placebo (matched to VX-121/TEZ/D-IVA), Placebo (matched to ELX/TEZ/IVA), Placebo (matched to IVA); Drug
Lead sponsor: Vertex Pharmaceuticals Incorporated; Industry
Eligibility: 12 Years and older
Enrollment: 597 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 62
States / cities: Birmingham, Alabama • Tucson, Arizona • Little Rock, Arkansas + 55 more

Conditions: Primary Immunodeficiency
Interventions: Gamunex-C, IVIG-PEG; Biological
Lead sponsor: Grifols Therapeutics LLC; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 10
States / cities: Birmingham, Alabama • North Palm Beach, Florida • South Bend, Indiana + 6 more

Conditions: Trauma, Patella Fracture, Knee Cap, Knee Cap Injury, Knee Discomfort, Knee Deformity
Interventions: Variable Angle LCP Patella Plating System, Traditional Fixation; Device
Lead sponsor: Hartford Hospital; Other
Eligibility: 18 Years to 74 Years
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: Hartford, Connecticut

Conditions: Sickle Cell Disease
Interventions: Not listed
Lead sponsor: National Heart, Lung, and Blood Institute (NHLBI); NIH
Eligibility: 18 Years to 99 Years
Enrollment: 94 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2018
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Gastroschisis
Interventions: Bifidobacteria infantis, Placebo; Dietary Supplement · Other
Lead sponsor: University of California, Davis; Other
Eligibility: Up to 2 Weeks
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2015
U.S. locations: 1
States / cities: Sacramento, California

Conditions: Hereditary Angioedema (HAE)
Interventions: DX-2930 - 300mg/2wk, DX-2930 - 300mg/4wk, DX-2930 - 150mg/4wk, Placebo; Drug
Lead sponsor: Shire; Industry
Eligibility: 12 Years and older
Enrollment: 125 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 31
States / cities: Birmingham, Alabama • Scottsdale, Arizona • San Diego, California + 28 more

Conditions: Chorioamnionitis
Interventions: saline, ampicillin gentamicin, ampicillin gentamicin clindamycin; Drug
Lead sponsor: United States Naval Medical Center, Portsmouth; Federal
Eligibility: 18 Years to 45 Years · Female only
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2012
U.S. locations: 1
States / cities: Portsmouth, Virginia

Conditions: Haemostasis, Congenital Bleeding Disorder, Haemophilia B
Interventions: No treatment given; Other
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 18 Years and older
Enrollment: 449 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015
U.S. locations: 1
States / cities: Plainsboro, New Jersey

Conditions: Neonatal Abstinence Syndrome
Interventions: Spark Biomedical Roo Transcutaneous Auricular Neurostimulation (tAN) System; Device
Lead sponsor: Spark Biomedical, Inc.; Industry
Eligibility: 33 Weeks to 1 Year
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020
U.S. locations: 1
States / cities: Charleston, South Carolina

Conditions: ADPKD
Interventions: Survey; Other
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years and older
Enrollment: 226 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Duchenne Muscular Dystrophy (DMD)
Interventions: SAT-3247; Drug
Lead sponsor: Satellos Bioscience, Inc.; Industry
Eligibility: 16 Years to 40 Years · Male only
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 4
States / cities: Los Angeles, California • St Louis, Missouri • Columbus, Ohio + 1 more

Search by objective public record fields.

An Observational Retrospective Cohort Study Being Conducted in Women With Atopic Dermatitis (AD)

Women At Risk: The High Risk Breast Cancer Program

Metformin and Rosiglitazone, Alone or in Combination, in HIV-Infected Patients With Insulin and Fat Abnormalities

Testing an Intelligent Tutoring System to Enhance Genetic Risk Assessment

A Study of Diazoxide Choline in Patients With Prader-Willi Syndrome

Clinical Effect, Safety and Tolerability of GSK1070806 in Atopic Dermatitis

Hemophilia Mobile App Usability Pilot

Long-term Safety and Efficacy Evaluation of IMG-007 in Participants With Moderate-to-Severe Atopic Dermatitis

Study of Immune Globulin Intravenous (Human) GC5107 in Pediatric Subjects With Primary Humoral Immunodeficiency

A Phase III, Crossover Trial Evaluating the Efficacy and Safety of KVD900 (Sebetralstat) for On-Demand Treatment of Angioedema Attacks in Adolescent and Adult Patients With Hereditary Angioedema (HAE)

Assessment of a PERT-free Nutritional Therapeutic Delivery System for Cystic Fibrosis

A Long-Term Follow-Up Study of Participants With Sickle Cell Disease or Transfusion Dependent β-Thalassemia Who Received EDIT-301

Extracellular Vesicles as Potential Biomarkers and Therapeutic Target in Gaucher Disease

A Study of VX-121 Combination Therapy in Participants With Cystic Fibrosis (CF) Who Are Homozygous for F508del, Heterozygous for F508del and a Gating (F/G) or Residual Function (F/RF) Mutation, or Have At Least 1 Other Triple Combination Responsive (TCR) CFTR Mutation and No F508del Mutation

A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Immune Globulin (Human) 10% (Gamunex-C) PEG Process (IVIG-PEG) Compared to Gamunex-C in Participants With Primary Humoral Immunodeficiency

DePuy Synthes Variable Angle LCP Patella Plating System Study

Blood Flow and Pain Crises in People With Sickle Cell Disease

Probiotics in Infants With Gastroschisis

Efficacy and Safety Study of DX-2930 to Prevent Acute Angioedema Attacks in Patients With Type I and Type II HAE

Treatment of Chorioamnionitis After Delivery

Bridging Hemophilia B Experiences, Results and Opportunities Into Solutions (B-HERO-S)

tAN to Mitigate Withdrawal Behaviors in Neonates

Genetic Testing in Autosomal Dominant Polycystic Kidney Disease

An Open-label Long-term Follow-up Study of SAT-3247 for Participants With Duchenne Muscular Dystrophy Including Those Who Participated in SAT-3247-CL-101